Dr. Nilesh V. Dubal studies the impacts of combining treatments on patients with metastatic anal cancer, which is a type of cancer that has spread beyond the anal region. He looks at how adding pelvic radiotherapy, a method that uses high-energy rays to kill cancer cells, to standard chemotherapy can affect patient survival and overall outcomes. By analyzing data from thousands of patients, his work aims to find more effective treatment plans that can significantly enhance the lives of those diagnosed with this challenging condition.
Key findings
Patients who received both pelvic radiotherapy and chemotherapy had a median survival of 21.3 months, compared to 15.9 months for those who received only chemotherapy.
The study included data from 1,457 patients diagnosed between 2004 and 2015.
Combining radiotherapy with chemotherapy may improve overall survival rates significantly for individuals with newly diagnosed metastatic anal cancer.
Frequently asked questions
Does Dr. Dubal study anal cancer?
Yes, Dr. Nilesh V. Dubal specializes in research focused on metastatic anal cancer and its treatment.
What treatments has Dr. Dubal researched?
He has researched the combination of pelvic radiotherapy and chemotherapy to improve survival outcomes for patients with metastatic anal cancer.
Is Dr. Dubal's work relevant to patients with metastatic anal cancer?
Absolutely, his research directly addresses treatment options that could enhance survival for patients diagnosed with this condition.
Publications in plain English
Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer.
2019
Journal of the National Comprehensive Cancer Network : JNCCN
Wang Y, Yu X, Zhao N, Wang J, Lin C +8 more
Plain English This study looked at how adding pelvic radiotherapy (RT) to chemotherapy affects survival in patients with newly diagnosed metastatic anal cancer, analyzing data from 1,457 patients between 2004 and 2015. It found that patients who received both RT and chemotherapy had a median survival of 21.3 months, compared to 15.9 months for those who only received chemotherapy. This matters because it shows that combining RT with chemotherapy can significantly improve survival rates for these patients.
Who this helps: This helps patients with metastatic anal cancer.